Maternal sirolimus therapy and fetal growth restriction

Fetal growth restriction associated with continued maternal sirolimus therapy in pregnancy has not been reported. We hereby present a case of maternal sirolimus therapy resulting in fetal growth restriction and propose a multi-hit model. This hypothetic model is based on inhibition of mTOR signaling...

Descripción completa

Detalles Bibliográficos
Autores principales: Tshering, Sangay, Dorji, Namkha, Youden, Sonam, Wangchuk, Dorji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: UMF “Gr. T. Popa” Iasi Publishing House 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565690/
https://www.ncbi.nlm.nih.gov/pubmed/34754935
http://dx.doi.org/10.22551/2021.31.0802.10180
Descripción
Sumario:Fetal growth restriction associated with continued maternal sirolimus therapy in pregnancy has not been reported. We hereby present a case of maternal sirolimus therapy resulting in fetal growth restriction and propose a multi-hit model. This hypothetic model is based on inhibition of mTOR signaling pathway and epigenetic modulation. This case report adds to the paucity of literature on continued monotherapeutic maternal sirolimus in pregnancy and its adverse fetal effects.

Ejemplares similares